Compare LDI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LDI | CTNM |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 480.5M |
| IPO Year | 2021 | 2024 |
| Metric | LDI | CTNM |
|---|---|---|
| Price | $1.42 | $12.73 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.8M | 303.4K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.58 | N/A |
| Revenue Next Year | $13.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $3.35 |
| 52 Week High | $5.05 | $16.33 |
| Indicator | LDI | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 44.71 |
| Support Level | $1.31 | $11.54 |
| Resistance Level | $1.96 | $13.18 |
| Average True Range (ATR) | 0.08 | 0.87 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 51.59 | 34.25 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.